This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2024 Apr 22:9:298-300.

doi: 10.1038/s41578-024-00681-2.

Leveraging next generation materials for cancer neuroscience therapies in the central nervous system

Joshua D Bernstock^{1

2}, Benjamin R Johnston¹, Gregory K Friedman³, E A Chiocca¹, Robert Langer², Shriya S Srinivasan⁴

Affiliations

Affiliations

¹ Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
³ Division of Pediatrics, Neuro-Oncology Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ John A. Paulson School of Engineering & Applied Sciences, Harvard University, Allston, MA, USA.

PMID: 39234424
PMCID: PMC11369983
DOI: 10.1038/s41578-024-00681-2

Leveraging next generation materials for cancer neuroscience therapies in the central nervous system

Joshua D Bernstock et al. Nat Rev Mater. 2024.

. 2024 Apr 22:9:298-300.

doi: 10.1038/s41578-024-00681-2.

Authors

Joshua D Bernstock^{1

2}, Benjamin R Johnston¹, Gregory K Friedman³, E A Chiocca¹, Robert Langer², Shriya S Srinivasan⁴

Affiliations

¹ Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
³ Division of Pediatrics, Neuro-Oncology Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ John A. Paulson School of Engineering & Applied Sciences, Harvard University, Allston, MA, USA.

PMID: 39234424
PMCID: PMC11369983
DOI: 10.1038/s41578-024-00681-2

No abstract available

PubMed Disclaimer

Figures

None — Cancer neuroscience treatment paradigm made possible with advanced local delivery. The potential for sustained delivery vehicles will be applied to cancer neuroscience applications (hydrogels, particles, microneedles, meshes). These tunable materials will help to limit spread of off-target effects of powerful therapeutics. From macro devices to micro mechanisms – the inset shows the main targets from cancer neuroscience discoveries focusing on neuron-glioma synapse promotion, synaptic activity, and post-synaptic network signaling of integrated circuits.

See this image and copyright information in PMC

References

1. Mancusi R. & Monje M. The neuroscience of cancer. Nature 618, 467–479, doi:10.1038/s41586-023-05968-y (2023). - DOI - PMC - PubMed
1. Winkler F. et al. Cancer neuroscience: State of the field, emerging directions. Cell 186, 1689–1707, doi:10.1016/j.cell.2023.02.002 (2023). - DOI - PMC - PubMed
1. Shi DD et al. Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncol 23, e62–e74, doi:10.1016/S1470-2045(21)00596-9 (2022). - DOI - PMC - PubMed
1. Venkatesh HS et al. Electrical and synaptic integration of glioma into neural circuits. Nature 573, 539–545, doi:10.1038/s41586-019-1563-y (2019). - DOI - PMC - PubMed
1. Krishna S. et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature, doi:10.1038/s41586-023-06036-1 (2023). - DOI - PMC - PubMed

Grants and funding

R01 FD006368/FD/FDA HHS/United States

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central